ABSTRACT
Background: Rosacea appears predominantly in highly visible areas of the facial region. Objective: To investigate the psychological status and quality of life(QOL) of rosacea. Methods: We used a hospital-based cross-sectional analytical study design between Jan 1, 2020, and Jan 1, 2021. We analyzed the differences and correlations in the severity of rosacea and its impacts on QOL and mental health, separately. Results: 469 patients with rosacea were included. The mean Dermatology Life Quality Index (DLQI) score was 12.6±7.7 and the affected level of DLQI was moderately severe. The total score of Rosacea-specific Quality-of-Life instrument (RosQol) was 2.34 ± 0.84, and the scores of emotion, symptoms, and function were 2.41 ± 0.99, 2.37 ±0.82, and 2.03 ± 0.89, respectively. 44.8% of patients suffered from anxiety and 37.5% from depression. There were statistically significant differences in the incidence of anxiety (p <0.001), the DLQL (p =0.02), RosQol emotion (p =0.04), symptom (p <0.01) and function (p =0.02) scores in the different severity. In addition, worsening QOL was significantly associated with increased disease severity [Spearman's rank correlation index (r) ranging from 0.171 to 0.266,p<0.01 (RosQol); r =0.104,p =0.024 (DLQI)]. There was also a positive correlation between anxiety [r =0.155; p<0.01] and the different severity levels. Conclusion: Rosacea maybe has a greater significant impact on patient's QOL and mental health. And the impact of QOL and mental health tend to deteriorate significantly with increasing disease severity. The relationship suggests that QOL assessment is of great interest in clinical practice and should be further explored.
ABSTRACT
BACKGROUND: Zinc has shown promise in the treatment of patients with viral warts in several clinical trials, but there is no consensus on its effectiveness. OBJECTIVE: To investigate the efficacy of various formulations of zinc on cutaneous warts. DATA SOURCES: We searched the Cochrane Central Register of Controlled Trials, EMBASE, PUBMED, and Web of Science without publishing-time restriction. Trials examining zinc in the treatment of warts were collected. RESULTS: Out of 265 articles, a total of 16 met inclusion criteria. Six clinical trials investigated the clinical effectiveness of oral zinc supplementation alone in treating viral warts, two trials evaluated the efficacy of oral zinc in combination with other therapy, five trials investigated the efficacy of intralesional zinc sulfate, and three trials investigated topical zinc treatment efficacy. Zinc therapy was found to be beneficial in 13 of 16 studies evaluating its effects on warts. CONCLUSIONS: The use of zinc is a simple, safe, and cost-effective treatment in viral warts based on some preliminary evidence. However, more well-designed studies need to be performed to further evaluate the effect of zinc on warts.
Subject(s)
Warts , Zinc , Administration, Topical , Humans , Papillomaviridae , Warts/drug therapy , Zinc/therapeutic use , Zinc Sulfate/therapeutic useSubject(s)
Hyperpigmentation , Keratosis, Seborrheic , Skin Diseases, Genetic , Skin Diseases, Papulosquamous , Humans , Hyperpigmentation/diagnosis , Hyperpigmentation/genetics , Keratosis, Seborrheic/diagnosis , Keratosis, Seborrheic/genetics , Skin Diseases, Genetic/diagnosis , Skin Diseases, Genetic/geneticsSubject(s)
Dermatitis, Atopic , Hypotrichosis , Keratosis , Membrane Proteins/genetics , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/genetics , Female , Genes, Tumor Suppressor , Growth Disorders/diagnosis , Growth Disorders/genetics , Humans , Hypotrichosis/diagnosis , Hypotrichosis/genetics , Infant , Keratosis/diagnosis , Keratosis/genetics , MutationABSTRACT
OBJECTIVE: To investigate the epidemiological and clinical features of multiple primary malignant neoplasms (MPMNs). METHODS: One hundred and twenty-five cases of more than or equal to three primary malignant neoplasms detected in the period of 1958 to 2001 were studied retrospectively in terms of frequency, age of onset, sex ratio, tumor location and the interval between sequential tumors. RESULTS: The overall incidence of MPMNs was 0.090%; for three, four and five MPMNs was 0.078%, 0.009% and 0.001%. The mean age of onset of MPMNs was 64 years. The sex ratio, of male to female, was 1.0:1.2. The mean time interval was 7.1 years, and it reduced from 5.7 to 2.4 years in a descending order of the first, second, third, forth and fifth primary tumors. Three, four and five primary malignant neoplasms were predicated respectively in the large intestine, breast, lung, esophagus, uterus, skin; the large intestine, breast, skin stomach, urinary bladder, uterus; and the large intestine, breast, skin, parotid glands. CONCLUSIONS: The overall incidence of multiple primary malignant neoplasms seems to ascend. The age of onset of MPMNs tends to be increase. The incidence of in women is higher than in men. The time interval from the first to fifth primary tumor is decreasing. The susceptible organs are identical organ, bigeminal organs or organs of the same system.
